Everolimus
Small molecule targets HIF1A, MTOR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (15) | US (FDA) | AFINITOR | — | 2010-10-29 – 2021-12-30 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ZORTRESS | — | 2013-02-15 – 2016-10-12 | fda.gov ↗ |
| Approved | EU (EMA) | Afinitor | — | 2009-08-02 | europa.eu ↗ |
| Approved | US (FDA) | AFINITOR | — | 2009-03-30 | fda.gov ↗ |
Trials 706 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT07095933 | Jul → Dec 2026 expected | epilepsy | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 0 | NCT06658093 | Mar 2026 → Jul 2028 expected | — | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT05432518 | Jun 2023 → Jul 2027 expected | adult glioblastoma | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 0 | NCT05188118 | Feb 2023 → Sep 2026 expected | renal cell carcinoma | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 0 | NCT05153668 | Sep 2022 → Oct 2025 | idiopathic subglottic stenosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT04135807 | Mar 2020 → Jan 2028 expected | anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma | Oliver Jonas | Recruiting | No outcome recorded |
| Phase 0 | NCT03834740 | Jan 2019 → Feb 2022 | brain glioma, glioblastoma | St. Joseph's Hospital and Medical Center, Phoenix | Completed | No outcome recorded |
| Phase 0 | NCT03578432 | May 2018 → Nov 2019 | head and neck cancer, salivary gland disorder | University of Arizona | Terminated | No outcome recorded |
| Phase 0 | NCT01880749 | Jun 2013 → Dec 2019 | NF2-related schwannomatosis, meningioma, vestibulocochlear nerve neoplasm | NYU Langone Health | Completed | No outcome recorded |
| Phase 1142 trials | ||||||
| Phase 1 | NCT07318324 | May 2026 → Aug 2028 expected | endometrial cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06832189 | Jan 2026 → Jun 2030 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT06994572 | May 2025 → Apr 2029 expected | hepatocellular carcinoma | Captor Therapeutics S.A. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05949658 | May 2024 → Mar 2027 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT05508906 | Aug 2022 → Dec 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, metastatic malignant neoplasm | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05293964 | May 2022 → Dec 2024 overdue | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04895748 | Nov 2021 → Feb 2026 | clear cell renal carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT04818632 | Nov 2021 → Sep 2023 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05490095 | Jul 2021 → Jan 2022 | — | Sovargen | Completed | No outcome recorded |
| Phase 1 | NCT04485559 | Dec 2020 → Dec 2027 expected | grade II glioma, high grade astrocytic tumor | University of California, San Francisco | Recruiting | No outcome recorded |
| Show all 142 trials opens the full record — a long page | ||||||
| Phase 1/283 trials | ||||||
| Phase 1/2 | NCT07435584 | Mar → Dec 2026 expected | colorectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07002177 | Jun 2025 → May 2028 expected | estrogen-receptor positive breast cancer | Forward Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06682611 | Nov 2024 → Nov 2026 expected | — | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05563220 | Jan 2023 → Dec 2026 expected | breast cancer | Stemline Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03697408 | Feb 2019 → May 2024 overdue | classic Hodgkin lymphoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03284957 | Sep 2017 → Nov 2024 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT02991807 | Jun 2017 → Feb 2021 | PTEN hamartoma tumor syndrome | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02985125 | May 2017 → Jul 2019 | pancreatic adenocarcinoma | Georgetown University | Completed | No outcome recorded |
| Phase 1/2 | NCT02711826 | Sep 2016 → Aug 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT02871791 | Aug 2016 → Dec 2020 | hormone receptor-positive breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02732119 | Jun 2016 → Feb 2020 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT02205515 | Mar 2016 → Sep 2021 | neuroendocrine carcinoma | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 1/2 | NCT02599324 | Dec 2015 → Aug 2021 | colorectal adenocarcinoma, gastric adenocarcinoma, renal cell carcinoma, urothelial carcinoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT02579044 | Dec 2015 → Mar 2027 expected | Hutchinson-Gilford progeria syndrome | Boston Children's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT02520063 | Feb 2015 → Dec 2022 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT01188889 | Sep 2013 → Dec 2016 | chronic myeloid leukemia | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01939418 | Aug 2013 → Jul 2016 | breast cancer | National Cancer Center, Korea | Terminated | No outcome recorded |
| Phase 1/2 | NCT01783756 | Jun 2013 → May 2019 | HER2 positive breast carcinoma, central nervous system cancer, male breast carcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01784861 | May 2013 → Aug 2020 | adenocarcinoma, pancreatic neuroendocrine neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT03629847 | Dec 2012 → Dec 2018 | neuroendocrine neoplasm | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01434602 | Oct 2012 → Oct 2020 | brain neoplasm, glioblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01231399 | Feb 2012 → Jul 2016 | diffuse gastric adenocarcinoma, esophageal adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01462214 | Oct 2011 → Jan 2017 | renal cell carcinoma | Hans J. van der Vliet, MD, PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT01510119 | Sep 2011 → Apr 2016 | clear cell renal carcinoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01427946 | Jul 2011 → Jun 2014 | non-small cell lung carcinoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01075321 | Jan 2011 → Feb 2015 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +12 | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01283334 | Jan 2011 → Nov 2013 | head and neck cancer | Emory University | Completed | No outcome recorded |
| Phase 1/2 | NCT01281865 | Jan 2011 → Oct 2013 | synovial sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01062399 | Dec 2010 → Jun 2016 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01259063 | Dec 2010 → Jun 2017 | urinary bladder cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01149434 | Sep 2010 → Aug 2012 | colorectal cancer, neuroendocrine neoplasm, ovarian cancer | University of Utah | Terminated | No outcome recorded |
| Phase 1/2 | NCT01136733 | Aug 2010 → Jun 2014 | renal cell carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01198665 | Jul 2010 → Dec 2014 | ALK-negative anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01139138 | Jun 2010 → Aug 2015 | colorectal carcinoma | The Queen Elizabeth Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01047293 | May 2010 → Aug 2015 | colorectal cancer | University of Utah | Completed | No outcome recorded |
| Phase 1/2 | NCT01125293 | Apr 2010 → Dec 2013 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01582009 | Mar 2010 → Oct 2015 | clear cell renal carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00574769 | Feb 2010 → Feb 2016 | prostate cancer | University of Southern California | Completed | No outcome recorded |
| Phase 1/2 | NCT01058655 | Feb 2010 → Sep 2013 | digestive system cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01009801 | Feb 2010 → Nov 2011 | liver cancer | Swiss Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01042028 | Jan 2010 → Nov 2012 | malignant pancreatic neoplasm | Per Pfeiffer | Terminated | No outcome recorded |
| Phase 1/2 | NCT01070316 | Jan 2010 → Apr 2016 | epilepsy, tuberous sclerosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT00968253 | Nov 2009 → Dec 2015 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00967044 | Nov 2009 → Mar 2014 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01333085 | Oct 2009 → Mar 2013 | head and neck cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01031446 | Oct 2009 → Dec 2011 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01009346 | Oct 2009 → Mar 2011 | head and neck cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1/2 | NCT01099527 | Oct 2009 → Aug 2013 | gastric cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01077986 | Aug 2009 → Aug 2010 | malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT00934895 | Jul 2009 → Jan 2014 | breast cancer | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 1/2 | NCT00935792 | Jul 2009 → Dec 2015 | B-cell chronic lymphocytic leukemia | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00918333 | Jun 2009 → Dec 2015 | B-cell adult acute lymphocytic leukemia, Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma +18 | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01313390 | Jun 2009 → Apr 2011 | head and neck cancer | University College, London | Terminated | No outcome recorded |
| Phase 1/2 | NCT00553150 | Mar 2009 → Jan 2012 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT01226056 | Mar 2009 → Sep 2012 | cancer | Southern Europe New Drug Organization | Suspended | No outcome recorded |
| Phase 1/2 | NCT00930475 | Feb 2009 → Dec 2010 | breast cancer | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 1/2 | NCT00792766 | Dec 2008 → Sep 2013 | angiolipoma, tuberous sclerosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT00576680 | May 2008 → Mar 2019 | pancreatic neuroendocrine tumor | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01079702 | Apr 2008 → Apr 2010 | cancer | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 1/2 | NCT00856505 | Mar 2008 → Mar 2010 | hematologic disorder | University Hospital Freiburg | Unknown | No outcome recorded |
| Phase 1/2 | NCT01514110 | Jan 2008 → Mar 2019 | gastric cancer | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 1/2 | NCT00762632 | Dec 2007 → Jun 2012 | acute myeloid leukemia | Technical University of Munich | Completed | No outcome recorded |
| Phase 1/2 | NCT00560963 | Oct 2007 → Jan 2011 | pancreatic adenocarcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00474929 | Aug 2007 → Nov 2011 | plasma cell neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00516165 | Aug 2007 → Jan 2010 | hepatocellular carcinoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00458237 | Apr 2007 → Apr 2010 | breast cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00411619 | Jan 2007 → Jan 2014 | subependymal giant cell astrocytoma, tuberous sclerosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT00392821 | Dec 2006 → Oct 2013 | kidney cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00448149 | Dec 2006 → Jun 2009 | renal cell carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00406276 | Nov 2006 → Dec 2010 | lung cancer | Emory University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00390195 | Oct 2006 → Jun 2010 | hepatocellular carcinoma | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
| Phase 1/2 | NCT00317720 | Apr 2006 → Feb 2013 | breast cancer, metastatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00459186 | Nov 2005 → Dec 2012 | metastatic prostate carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00457964 | Aug 2005 → Jul 2013 | lymphangioleiomyomatosis, tuberous sclerosis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/2 | NCT00093639 | Aug 2004 → Aug 2006 | myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00096486 | May 2004 → Jul 2010 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00081874 | Apr 2004 → Sep 2006 | leukemia, mantle cell lymphoma, myelofibrosis | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00085566 | Mar 2004 → Feb 2008 | central nervous system neoplasm, prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00107237 | Oct 2003 → Jun 2006 | central nervous system neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01275222 | Nov 2002 → Sep 2008 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2281 trials | ||||||
| Phase 2 | NCT07634601 | Dec 2026 → Dec 2028 expected | endometrial carcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07522801 | Sep 2026 → Dec 2029 expected | — | Philippe ROUSSELOT | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07619950 | Jul 2026 → Nov 2028 expected | bone cancer | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07124078 | May 2026 → Jan 2029 expected | chronic graft versus host disease | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT07477548 | Apr 2026 → Oct 2030 expected | arteriovenous hemangioma/malformation, hemangioendothelioma, lymphangioma, non-neoplastic nevus +2 | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07340541 | Feb 2026 → Jun 2031 expected | estrogen-receptor positive breast cancer, triple-negative breast carcinoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07191353 | Oct 2025 → Mar 2027 expected | osteoporosis | Odense University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07037238 | Jul 2025 → Jul 2026 overdue | vascular malformation | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2 | NCT06972758 | Jul 2025 → Jul 2030 expected | hepatocellular carcinoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06730672 | Dec 2024 → Dec 2027 expected | renal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Show all 281 trials opens the full record — a long page | ||||||
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT07218575 | Sep 2026 → Sep 2030 expected | Bannayan-Riley-Ruvalcaba syndrome, Cowden disease, Lhermitte-Duclos disease, Martsolf syndrome +1 | Boston Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03458221 | Jan 2023 → Oct 2026 expected | ovarian cancer | Gynaecologisch Oncologisch Centrum Zuid | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05833815 | Nov 2022 → Dec 2024 overdue | gallbladder cancer | Banaras Hindu University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02860494 | Dec 2020 → Dec 2023 | vascular neoplasm | Hospices Civils de Lyon | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03285802 | Sep 2017 → Feb 2019 | uterine cancer | Greater Baltimore Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01878786 | Jun 2013 → Nov 2017 | — | Matthew Cooper | Terminated | No outcome recorded |
| Phase 2/3 | NCT01730209 | Nov 2012 → Nov 2015 | autism, tuberous sclerosis | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 2/3 | NCT01023542 | Jun 2011 → Jul 2014 | impaired renal function disease | University of Regensburg | Unknown | No outcome recorded |
| Phase 2/3 | NCT01009957 | Jun 2008 → Jan 2014 | autosomal dominant polycystic kidney disease | A. Manzoni Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT00117702 | Oct 2005 → May 2008 | graft versus host disease | Technical University Dresden | Terminated | No outcome recorded |
| Phase 380 trials | ||||||
| Phase 3 | NCT07407517 | Feb 2026 → Feb 2033 expected | female breast carcinoma, triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07239271 | Nov 2025 → Dec 2027 expected | HER2 positive breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07165418 | Sep 2025 → Dec 2028 expected | renal cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06382948 | Dec 2024 → Sep 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 3 | NCT06680921 | Nov 2024 → Aug 2028 expected | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05954442 | Sep 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04258423 | Dec 2019 → Jun 2020 | kidney failure | Indiana University | Terminated | No outcome recorded |
| Phase 3 | NCT03839940 | Jun 2019 → Jan 2021 | cancer | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 3 | NCT04063865 | May 2019 → Jul 2020 | kidney failure | Indiana University | Terminated | No outcome recorded |
| Phase 3 | NCT03580239 | Jan 2019 → Jan 2023 | prostate cancer | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03386539 | Jan 2018 → Apr 2023 overdue | chronic kidney disease, disease related to solid organ transplantation, immunodeficiency disease, post-transplant lymphoproliferative disease +1 | Boston Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02962414 | Jun 2017 → Aug 2027 expected | tuberous sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02811861 | Oct 2016 → Aug 2020 overdue | renal cell carcinoma | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02404051 | Dec 2015 → Jan 2018 | hormone receptor-positive breast cancer, secondary malignant neoplasm | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 3 | NCT02246127 | Oct 2014 → Nov 2020 | neuroendocrine neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Completed | No outcome recorded |
| Phase 3 | NCT02134899 | Oct 2014 → Nov 2017 | autosomal dominant polycystic kidney disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02511639 | Jul 2014 → Feb 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 3 | NCT02137837 | May 2014 → Dec 2019 | breast cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT02115113 | Mar 2014 → Sep 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02040584 | Dec 2013 → Feb 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01888432 | Sep 2013 → Oct 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01674140 | Sep 2013 → Dec 2022 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01773460 | Jul 2013 → Jul 2014 | breast cancer | GBG Forschungs GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT01636466 | Jun 2013 → May 2014 | chronic renal failure syndrome | Ashtar Chami | Terminated | No outcome recorded |
| Phase 3 | NCT01713946 | Apr 2013 → Oct 2017 | tuberous sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03176238 | Mar 2013 → Jan 2019 | breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01805271 | Mar 2013 → Jun 2020 overdue | Her2-receptor negative breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01843348 | Dec 2012 → Mar 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01625377 | Dec 2012 → Mar 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01680861 | Nov 2012 → Dec 2014 | — | Gaetano Ciancio | Completed | No outcome recorded |
| Phase 3 | NCT01598987 | Oct 2012 → Jun 2016 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01707849 | Oct 2012 → Aug 2016 | acute hepatitis C virus infection | Hospital Vall d'Hebron | Completed | No outcome recorded |
| Phase 3 | NCT01544491 | Aug 2012 → Oct 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01626222 | Jun 2012 → Nov 2013 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01595984 | May 2012 → Mar 2024 | kidney failure | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT01524783 | Mar 2012 → Nov 2014 | digestive system neuroendocrine neoplasm, lung neuroendocrine neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01404325 | Feb 2012 → Jan 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02314312 | Jan 2012 → Jun 2015 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT01410448 | Nov 2011 → Dec 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01248403 | Oct 2011 → Jul 2017 | gastric cancer, gastroesophageal cancer | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 3 | NCT01120249 | Apr 2011 → Jul 2023 | kidney cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT01198158 | Sep 2010 → Dec 2017 | clear cell renal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT01114529 | Aug 2010 → Oct 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01035229 | Apr 2010 → Oct 2013 | carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01150097 | Mar 2010 → May 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01025817 | Jan 2010 → Mar 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01007942 | Oct 2009 → Jun 2015 | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00876395 | Sep 2009 → May 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01079143 | Sep 2009 → Jun 2012 | renal fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00789828 | Aug 2009 → Mar 2011 | subependymal giant cell astrocytoma, tuberous sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00790036 | Jul 2009 → Jun 2016 | diffuse large B-cell lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00879333 | Jul 2009 → Jan 2014 | gastric cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00863655 | Jun 2009 → Dec 2014 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00966836 | Apr 2009 → Apr 2012 | cytomegalovirus infection | University of Bologna | Unknown | No outcome recorded |
| Phase 3 | NCT01023815 | Apr 2009 → Jul 2012 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00790400 | Apr 2009 → Jun 2011 | lymphangioleiomyomatosis, tuberous sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01028092 | Mar 2009 → Mar 2014 | — | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT00799188 | Oct 2008 → Aug 2014 | skin cancer | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT00658320 | Feb 2008 → Aug 2010 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00622869 | Jan 2008 → Apr 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00567554 | Oct 2007 → Aug 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00510068 | Jul 2007 → Feb 2010 | pancreatic neuroendocrine tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00514514 | Jul 2007 → Jun 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00412061 | Dec 2006 → Apr 2010 | carcinoid syndrome, carcinoid tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00410124 | Nov 2006 → Feb 2008 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00426049 | Oct 2006 → ? | coronary restenosis | German Heart Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00464399 | Sep 2006 → Dec 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01276457 | May 2006 → Feb 2009 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00300274 | Jan 2006 → Jul 2011 | transplant rejection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00251004 | Oct 2005 → Aug 2009 | transplant rejection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00154284 | Jul 2005 → Jul 2008 | disease related to solid organ transplantation | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00150046 | Dec 2004 → May 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00170794 | Sep 2004 → Jul 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00098007 | Aug 2004 → Jan 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00097968 | Aug 2004 → Apr 2005 | transplant rejection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00170833 | Nov 2003 → Nov 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00531063 | Nov 2001 → Aug 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00531440 | Nov 2001 → Aug 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00098241 | Jun 2000 → Mar 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 474 trials | ||||||
| Phase 4 | NCT07570433 | Apr 2026 → Jan 2028 expected | cytomegalovirus infection | Oriol Manuel | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06942156 | Aug 2025 → Dec 2030 expected | — | Chong Kun Dang Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05252585 | May 2023 → Oct 2026 expected | kidney angiomyolipoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04849533 | Apr 2021 → Jul 2023 | transplant rejection | University of Cincinnati | Unknown | No outcome recorded |
| Phase 4 | NCT04867720 | Mar 2021 → Oct 2022 | — | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT04471441 | Jun 2020 → Jul 2024 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT04177095 | Feb 2020 → Sep 2021 | transplant rejection | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03797196 | Jul 2019 → Jun 2025 overdue | disease related to solid organ transplantation | University Medical Center Groningen | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03525834 | Nov 2018 → Sep 2020 | kidney angiomyolipoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT03216967 | Jan 2018 → Aug 2024 | BK-virus nephropathy | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT03468478 | Jun 2017 → Mar 2021 | disease related to solid organ transplantation | Hospital do Rim e Hipertensão | Completed | No outcome recorded |
| Phase 4 | NCT03415750 | Nov 2016 → May 2020 | — | Edoardo Melilli | Completed | No outcome recorded |
| Phase 4 | NCT02842749 | Mar 2016 → Feb 2024 | pancreatic neuroendocrine tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02429869 | Feb 2016 → Jan 2018 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02864706 | Jan 2016 → Sep 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT03256864 | Jan 2016 → Jun 2019 | — | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02493465 | Jul 2015 → Jul 2016 | — | Instituto de Urologia e Nefrologia | Unknown | No outcome recorded |
| Phase 4 | NCT02338570 | Jul 2015 → Feb 2018 | renal cell carcinoma | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 4 | NCT06584773 | Jun 2015 → Aug 2024 overdue | disease related to solid organ transplantation | University of Sao Paulo General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02248571 | Aug 2014 → Aug 2017 | female breast carcinoma, hormone receptor-positive breast cancer | iOMEDICO AG | Completed | No outcome recorded |
| Phase 4 | NCT02328963 | May 2014 → Oct 2018 | cytomegalovirus infection, disease related to solid organ transplantation | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 4 | NCT02077556 | Apr 2014 → Jan 2019 | — | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02081755 | Mar 2014 → Mar 2027 expected | hepatocellular carcinoma | Baylor Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01950819 | Dec 2013 → Feb 2017 | end stage renal failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02062892 | Dec 2013 → Jun 2014 | — | University of Colorado, Denver | Withdrawn | No outcome recorded |
| Phase 4 | NCT01895049 | Aug 2013 → Mar 2016 | cytomegalovirus infection | Helio Tedesco Silva Junior | Completed | No outcome recorded |
| Phase 4 | NCT01927588 | Aug 2013 → Nov 2015 | cytomegalovirus infection | Fundação Pró Rim | Unknown | No outcome recorded |
| Phase 4 | NCT01935128 | Jul 2013 → Jul 2020 | — | University of Toledo Health Science Campus | Completed | No outcome recorded |
| Phase 4 | NCT01789281 | May 2013 → Aug 2020 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02036554 | Mar 2013 → Dec 2015 | — | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01743560 | Jan 2013 → Aug 2016 | estrogen-receptor positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02084446 | Dec 2012 → Jul 2014 | cytomegalovirus infection, disease related to solid organ transplantation | Ronaldo de Matos Esmeraldo, MD | Completed | No outcome recorded |
| Phase 4 | NCT01624948 | Sep 2012 → Feb 2015 | polyomavirus infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01653041 | Aug 2012 → Aug 2014 | — | Hospital do Rim e Hipertensão | Completed | No outcome recorded |
| Phase 4 | NCT01631058 | Jul 2012 → Jul 2014 | chronic renal failure syndrome, transplant rejection | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01551212 | May 2012 → Aug 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01514448 | May 2012 → Apr 2016 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01594268 | Mar 2012 → Oct 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01469884 | Nov 2011 → Apr 2015 | hepatitis C virus infection | Irmandade Santa Casa de Misericórdia de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT02056587 | Nov 2011 → Apr 2013 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 4 | NCT01455649 | Nov 2011 → Nov 2013 | — | Deise de Boni Monteiro de Carvalho | Unknown | No outcome recorded |
| Phase 4 | NCT01289301 | Oct 2011 → Oct 2017 | disease related to solid organ transplantation, immunodeficiency-related disorder, viral infectious disease | Hannover Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT01561404 | Sep 2011 → Dec 2013 | disease related to solid organ transplantation | Josep m Cruzado | Terminated | No outcome recorded |
| Phase 4 | NCT01354301 | May 2011 → Apr 2014 | cytomegalovirus infection, transplant rejection | Hospital do Rim e Hipertensão | Completed | No outcome recorded |
| Phase 4 | NCT01595009 | Apr 2011 → Aug 2016 | neuroendocrine neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01317615 | Apr 2011 → Mar 2015 | large cell carcinoma, neuroendocrine neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01266837 | Mar 2011 → Sep 2017 | clear cell renal carcinoma | iOMEDICO AG | Completed | No outcome recorded |
| Phase 4 | NCT01276834 | Sep 2010 → Jul 2012 | — | Dianet Dialysis Centers | Terminated | No outcome recorded |
| Phase 4 | NCT01169701 | Aug 2010 → Mar 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00965094 | Dec 2009 → Jun 2013 | chronic renal failure syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01206764 | Nov 2009 → Jun 2017 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01266148 | Nov 2009 → Dec 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01017029 | Sep 2009 → Dec 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00956293 | Jul 2009 → Mar 2013 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01706471 | Jun 2009 → Jan 2013 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00862979 | Feb 2009 → Mar 2017 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00716573 | Sep 2008 → Apr 2014 | chronic renal failure syndrome | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT01269684 | Aug 2008 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT00634920 | Mar 2008 → May 2013 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00596557 | Feb 2008 → Feb 2009 | chronic transplant rejection | Rabin Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00812786 | Jul 2007 → May 2011 | — | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00443508 | Feb 2007 → Feb 2010 | kidney disorder | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00414440 | Dec 2006 → Oct 2013 | autosomal dominant polycystic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00371826 | Mar 2006 → Jun 2012 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00695344 | Jan 2006 → Jun 2010 | — | Fundacion Investigacion y Desarrollo | Unknown | No outcome recorded |
| Phase 4 | NCT00377962 | Dec 2005 → Feb 2010 | disease related to solid organ transplantation | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00332839 | Nov 2005 → Mar 2013 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT00154297 | Jun 2005 → Jun 2008 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00154310 | Jun 2005 → Sep 2008 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00170885 | May 2005 → Jul 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00170846 | Feb 2005 → Oct 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00170820 | Feb 2005 → Mar 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00170859 | Aug 2004 → Nov 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00443937 | Jan 2004 → Mar 2006 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07144150 | Apr 2026 → Sep 2028 expected | peripheral arterial disease | Cook Research Incorporated | Recruiting | No outcome recorded |
| — | NCT04199026 | Feb 2025 → Dec 2028 expected | sarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT06317298 | Feb 2024 → Aug 2025 | clear cell renal carcinoma | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT03955172 | Dec 2020 → Dec 2027 expected | chronic transplant rejection | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| — | NCT04906304 | Jan → Jul 2020 | cytomegalovirus infection | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT02736227 | Mar 2016 → Mar 2021 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02109913 | Mar 2014 → Jan 2021 | hormone receptor-positive breast cancer | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| — | NCT01936519 | Dec 2013 → Jul 2019 | immunodeficiency disease, kidney failure | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02015728 | Dec 2013 → Nov 2016 | brain cancer | Seattle Children's Hospital | Unknown | No outcome recorded |
| — | NCT01807767 | Mar 2013 → Jul 2015 | — | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| — | NCT01780948 | Sep 2012 → Jan 2013 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01566279 | Aug 2012 → Nov 2015 | cancer of unknown primary site | UMC Utrecht | Completed | No outcome recorded |
| — | NCT01612299 | May 2012 → Dec 2013 | — | University of Kentucky | Withdrawn | No outcome recorded |
| — | NCT01473732 | Mar → Aug 2012 | chronic transplant rejection, poisoning | Montefiore Medical Center | Terminated | No outcome recorded |
| — | NCT01636908 | Aug 2011 → Jan 2018 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01107509 | Oct 2010 → Oct 2017 | renal cell carcinoma | St. Joseph's Healthcare Hamilton | Completed | No outcome recorded |
| — | NCT01190241 | Aug 2010 → Dec 2017 | cancer, metastatic neoplasm | Amsterdam UMC, location VUmc | Terminated | No outcome recorded |
| — | NCT02091973 | Jun 2010 → Dec 2015 | — | Chulalongkorn University | Unknown | No outcome recorded |
| — | NCT01640743 | Mar 2010 → Jun 2013 | — | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| — | NCT00828087 | Dec 2008 → May 2015 | myocardial infarction | Spanish Society of Cardiology | Completed | No outcome recorded |
| Phase not stated5 trials | ||||||
| — | NCT05108740 | — | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | No longer available | No outcome recorded |
| — | NCT03493165 | — | uterine corpus sarcoma | The University of Texas Health Science Center at San Antonio | No longer available | No outcome recorded |
| — | NCT00655252 | — | renal cell carcinoma | Novartis Pharmaceuticals | No longer available | No outcome recorded |
| — | NCT00149981 | — | disease related to solid organ transplantation | Novartis Pharmaceuticals | No longer available | No outcome recorded |
| — | NCT03493152 | — | gastrointestinal stromal tumor | The University of Texas Health Science Center at San Antonio | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 116 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02134288 Comparator | Apr 2014 → Dec 2018 | — | Ohio State University | Terminated | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05501769 Background | Sep 2022 → Jul 2024 | breast cancer | Arvinas Estrogen Receptor, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05189717 Background | Feb 2022 → Oct 2024 | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02577458 Background | Sep 2015 → Mar 2018 | renal cell carcinoma | AnewPharma | Unknown | No outcome recorded |
| Phase 1 | NCT02454478 Background | Jul 2015 → May 2017 | renal cell carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02188719 Background | Dec 2014 → Jun 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT02123823 Background | May 2014 → Nov 2016 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02071862 Background | Feb 2014 → Mar 2019 | gastrointestinal stromal tumor, mesothelioma, non-small cell lung carcinoma, renal cell carcinoma +1 | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01677390 Background | Aug 2012 → Dec 2013 | renal cell carcinoma | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00401778 Comparator | Nov 2006 → Dec 2013 | lung cancer | Emory University | Completed | No outcome recorded |
| Phase 1/217 trials | ||||||
| Phase 1/2 | NCT06727305 Comparator | May 2026 → Sep 2027 expected | — | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07173556 Background | Sep 2025 → Feb 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05573126 Background | Jan 2023 → Feb 2028 expected | hormone receptor-positive breast cancer | Ellipses Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03654040 Background | Apr 2021 → Mar 2023 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/2 | NCT04339062 Background | Nov 2020 → Jun 2023 | skin squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT04066114 Background | Dec 2019 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/2 | NCT03577431 Background | Mar 2019 → Feb 2026 overdue | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03245151 Background | Nov 2017 → Sep 2022 | refractory malignant neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01529554 Comparator | Jan 2015 → Nov 2021 | acute coronary syndrome | University of Zurich | Completed | No outcome recorded |
| Phase 1/2 | NCT02061397 Background | Mar 2014 → Dec 2019 | lymphangioleiomyomatosis, tuberous sclerosis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT01453504 Comparator | Aug 2012 → Mar 2019 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 1/2 | NCT01446484 Background | Oct 2011 → Nov 2014 | end stage renal failure, kidney failure | Pirogov Russian National Research Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01175096 Comparator | Jul 2010 → Jan 2012 | carcinoid tumor | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01034631 Comparator | Jan 2010 → Dec 2016 | renal cell carcinoma | Hoosier Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00522665 Comparator | Aug 2007 → May 2011 | colorectal cancer | Hoosier Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT00286624 Background | Mar 2003 → Aug 2006 | hypoglycemia, type 1 diabetes mellitus | University of Minnesota | Completed | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT06849947 Comparator | Feb 2026 → Jun 2031 expected | breast carcinoma | Yeon Hee Park | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06254248 Background | Jan 2026 → Jan 2030 expected | hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT06552169 Comparator | Jun 2025 → Dec 2027 expected | — | Singulera Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06326190 Comparator | Mar 2025 → Apr 2027 expected | meningioma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 2 | NCT06428396 Comparator | Nov 2024 → May 2027 expected | breast cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05773274 Comparator | Jan 2024 → Apr 2029 expected | digestive system neuroendocrine tumor, grade 1/2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06105632 Comparator | Jan 2024 → Jan 2026 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05079360 Comparator | Mar 2023 → Mar 2024 | breast cancer | Veru Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04665739 Comparator | Feb 2023 → Jul 2027 expected | lung neuroendocrine neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04118556 Comparator | Dec 2021 → Apr 2026 | acute graft versus host disease | Mats Remberger | Terminated | No outcome recorded |
| Phase 2 | NCT04203901 Background | Jul 2020 → Sep 2023 | renal cell carcinoma | CoImmune | Terminated | No outcome recorded |
| Phase 2 | NCT03659136 Background | Nov 2018 → Aug 2021 | breast cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT03163667 Comparator | Sep 2017 → Apr 2019 | clear cell renal carcinoma | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02970630 Background | Jan 2017 → Feb 2018 | — | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02724020 Comparator | Jun 2016 → Feb 2020 | clear cell renal carcinoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02258451 Background | Jun 2015 → Jan 2020 | breast cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02187302 Comparator | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02069093 Background | May 2014 → Mar 2016 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02216786 Comparator | Jan 2014 → Dec 2021 | estrogen-receptor positive breast cancer | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT01797120 Comparator | May 2013 → Mar 2017 | breast cancer | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT01793636 Comparator | Feb 2013 → May 2014 | clear cell renal carcinoma | Queen Mary University of London | Terminated | No outcome recorded |
| Phase 2 | NCT01628913 Comparator | Oct 2012 → Sep 2014 | pancreatic neuroendocrine tumor | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01442090 Comparator | Oct 2011 → May 2013 | renal cell carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01215136 Comparator | Dec 2010 → Apr 2017 | urinary bladder carcinoma, urothelial carcinoma | Matthew Galsky | Terminated | No outcome recorded |
| Phase 2 | NCT01376310 Background | Nov 2010 → Jan 2018 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01108445 Comparator | Sep 2010 → Feb 2015 | renal cell carcinoma | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01157858 Comparator | Jun 2010 → Jul 2012 | liver disorder | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00915603 Comparator | Jul 2009 → Jun 2014 | Her2-receptor negative breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00828503 Comparator | Dec 2008 → Dec 2013 | cytomegalovirus infection | Marcus Saemann | Unknown | No outcome recorded |
| Phase 2 | NCT00820911 Background | Sep 2008 → Jul 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00504543 Comparator | Jul 2007 → Apr 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00466102 Comparator | Dec 2006 → Dec 2010 | breast cancer | GBG Forschungs GmbH | Unknown | No outcome recorded |
| Phase 2 | NCT00255788 Comparator | May 2005 → Jul 2008 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07165886 Comparator | Aug 2025 → Aug 2028 expected | digestive system neuroendocrine neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06943755 Comparator | Jul 2025 → Jun 2029 expected | pancreatic neuroendocrine tumor | Exelixis | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05522231 Comparator | Oct 2022 → Jan 2025 overdue | renal cell carcinoma | Hutchmed | Active not recruiting | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07062965 Comparator | Aug 2025 → Jul 2027 expected | breast cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT07024173 Comparator | Jul 2025 → Dec 2026 expected | female breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06821542 Background | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05918302 Comparator | Oct 2023 → Mar 2029 expected | lung neuroendocrine neoplasm, thymus neoplasm | Spanish Group for Research in Neuroendocrine Tumors | Recruiting | No outcome recorded |
| Phase 3 | NCT05476939 Comparator | Sep 2022 → Sep 2028 expected | diffuse midline glioma, H3 K27M-mutant | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05306340 Background | Aug 2022 → Jul 2025 overdue | estrogen-receptor positive breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05065411 Comparator | Apr 2022 → Oct 2023 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05477576 Comparator | Mar 2022 → Dec 2026 expected | carcinoid tumor, pancreatic neuroendocrine tumor | RayzeBio, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04919226 Comparator | Dec 2021 → Jun 2027 expected | neuroendocrine neoplasm | ITM Solucin GmbH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04869943 Comparator | Oct 2021 → Jan 2024 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04629833 Comparator | Aug 2021 → Aug 2027 expected | acute graft versus host disease | medac GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT04195750 Comparator | Feb 2020 → Apr 2024 overdue | renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03112603 Comparator | Jun 2017 → May 2020 | chronic graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02913261 Comparator | Mar 2017 → Jun 2019 | acute graft versus host disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03049189 Comparator | Feb 2017 → Nov 2024 overdue | neuroendocrine neoplasm | ITM Solucin GmbH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03095040 Comparator | Dec 2016 → Feb 2021 | renal cell carcinoma | AnewPharma | Unknown | No outcome recorded |
| Phase 3 | NCT02909335 Comparator | Nov 2016 → Nov 2021 | — | Rennes University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT03596970 Comparator | Sep 2015 → Dec 2020 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02376985 Background | Mar 2015 → Mar 2018 | female breast carcinoma | Comprehensive Support Project for Oncology Research | Completed | No outcome recorded |
| Phase 3 | NCT02334488 Background | Dec 2014 → May 2019 | chronic kidney disease | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01865747 Comparator | Jun 2013 → May 2015 | renal cell carcinoma | Exelixis | Completed | No outcome recorded |
| Phase 3 | NCT01668784 Comparator | Oct 2012 → May 2015 | clear cell renal carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00425308 Comparator | Oct 2006 → May 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00378014 Comparator | Aug 2006 → Jan 2013 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00267189 Comparator | Nov 2005 → Nov 2007 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00402532 Comparator | Mar 2005 → Nov 2011 | — | Hannover Medical School | Completed | No outcome recorded |
| Phase 419 trials | ||||||
| Phase 4 | NCT07426484 Background | Jul 2026 → Dec 2030 expected | skin squamous cell carcinoma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04936971 Comparator | Sep 2021 | cytomegalovirus infection | Edoardo Melilli | Withdrawn | No outcome recorded |
| Phase 4 | NCT04104438 Comparator | Jan 2021 → Sep 2024 | — | Fady M Kaldas, M.D., F.A.C.S. | Completed | No outcome recorded |
| Phase 4 | NCT02974686 Comparator | Nov 2016 → Sep 2019 | digestive system disorder, transplant rejection | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 4 | NCT02338609 Background | Dec 2014 → Dec 2023 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02096107 Comparator | Feb 2014 → May 2017 | disease related to transplantation, renal fibrosis | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT01948960 Comparator | Aug 2013 → Jan 2018 | breast neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01608412 Comparator | Feb 2012 → Jul 2014 | disease related to solid organ transplantation | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT01663805 Comparator | Jan 2012 → Dec 2014 | disease related to solid organ transplantation | MARIO ABBUD FILHO | Unknown | No outcome recorded |
| Phase 4 | NCT01399242 Comparator | Aug 2011 → Jun 2012 | disease related to solid organ transplantation | Hospital Universitário São José | Unknown | No outcome recorded |
| Phase 4 | NCT01312064 Comparator | Apr 2011 → Apr 2012 | impaired renal function disease | National Taiwan University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01239472 Comparator | Jan 2011 → Jun 2015 | transplant rejection | Andre Barreto Pereira | Completed | No outcome recorded |
| Phase 4 | NCT00903188 Comparator | Oct 2008 → Apr 2010 | — | University Hospital, Antwerp | Unknown | No outcome recorded |
| Phase 4 | NCT01183247 Comparator | Jul 2008 → Jun 2010 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT01046045 Comparator | Apr 2008 → Nov 2011 | chronic kidney disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00505102 Comparator | Jan 2007 → Jul 2009 | kidney disorder | A.O. Ospedale Papa Giovanni XXIII | Unknown | No outcome recorded |
| Phase 4 | NCT00420537 Comparator | Sep 2006 → Jan 2009 | impaired renal function disease | University of Bologna | Terminated | No outcome recorded |
| Phase 4 | NCT00369161 Comparator | Jun 2006 → Dec 2008 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00160966 Comparator | Sep 2004 → Mar 2010 | polyomavirus infectious disease | University of Giessen | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT04542733 Comparator | Jun 2023 → Dec 2027 expected | disease related to solid organ transplantation, polyomavirus infectious disease | King Chulalongkorn Memorial Hospital | Active not recruiting | No outcome recorded |
| — | NCT02954198 Comparator | Dec 2016 → Dec 2018 | immunodeficiency disease | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT02450175 Comparator | Jun 2014 → Jun 2016 | neoplasm | Sinai Hospital of Baltimore | Unknown | No outcome recorded |
| — | NCT02208128 Comparator | May 2014 → Feb 2018 | renal cell carcinoma | Heidelberg University | Unknown | No outcome recorded |
| — | NCT01976390 Comparator | Oct 2013 → Jul 2018 | kidney failure | Ohio State University | Completed | No outcome recorded |
| — | NCT01609673 Comparator | Mar → May 2013 | end stage renal failure | Helady Pinheiro, MD, PhD | Terminated | No outcome recorded |
| — | NCT01653847 Comparator | Feb 2013 → May 2020 | end stage renal failure | Northwestern University | Completed | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-01-31 | Novartis Pharmaceuticals | Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC novartis.com ↗ |
| 2016-12-16 | Novartis Pharmaceuticals | Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC novartis.com ↗ |
| 2016-06-02 | Novartis Pharmaceuticals | Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET) novartis.com ↗ |
| 2016-04-29 | Novartis Pharmaceuticals | Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors novartis.com ↗ |
| 2016-04-20 | Novartis Pharmaceuticals | Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex novartis.com ↗ |
| 2016-02-26 | Novartis Pharmaceuticals | FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET) novartis.com ↗ |
| 2015-09-27 | Novartis Pharmaceuticals | Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET novartis.com ↗ |
| 2015-05-29 | Pfizer | Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease pfizer.com ↗ |
| 2015-05-21 | Novartis Pharmaceuticals | Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors novartis.com ↗ |
| 2015-02-20 | Pfizer | FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM) pfizer.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 852 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | everolimus | “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗718“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗ “A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation...” NCT02040584 ↗ “We have recently demonstrated that RAD001(everolimus),an mTOR inhibitor, although with only modest growth inhibitory effects as a single agent, has significant synergistic...” NCT00632268 ↗ “Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗ “In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026 “Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of...” NCT04177095 ↗ “Participants with PIK3CA gene mutations will receive a drug called Everolimus, which inhibits a protein called AKT that is thought to be a key factor in the development and...” NCT02208583 ↗ “We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line...” PMID 19047305 ↗ Dec 2008 “Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously...” NCT00935961 ↗ “The RAPTOR (RAD001 in Advanced Papillary Tumor Program in Europe; ClinicalTrials.gov, NCT00688753) study evaluated first-line everolimus in patients with papillary metastatic...” PMID 27680407 ↗ Sep 2016 “Combination of everolimus also known as RAD001 (oral mammalian target of rapamycin (mTOR) inhibitor) and carboplatin may have activity in metastatic triple-negative breast...” PMID 24684785 ↗ Mar 2014 “The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.” NCT00849550 ↗ “Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.” NCT01936519 ↗ “After diagnosis of cGvHD patients will receive prednisone 1 mg/kg BW orally and everolimus (whole tablets or dispersible tablets) orally (targeted trough level 3-8 µg/l).” NCT01862965 ↗ “This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer.” NCT00374140 ↗ “Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)” NCT01950819 ↗ “Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017 “RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.” PMID 23725999 ↗ May 2013 “This study aims to evaluate the efficacy and safety of everolimus (Certirobell®) as adjuvant therapy in high-risk HCC patients following curative resection.” NCT06972758 ↗ “Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3.” NCT05826964 ↗ “Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant” NCT01544491 ↗ “Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab” NCT04339062 ↗ “Everolimus, an oral inhibitor of mammalian target of rapamycin, can augment the efficacy of HER inhibitors in preclinical studies.” PMID 24057042 ↗ Sep 2013 “a switch from MPA to a mammalian target of rapamycin inhibitor (mTORi) everolimus, together with an adapted dose of tacrolimus” NCT07570433 ↗ “Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease.” NCT01283789 ↗ “Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors” NCT01482156 ↗ “Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.” PMID 23475104 ↗ Mar 2013 “Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma” NCT00622258 ↗ “RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability” NCT00729482 ↗ “whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001).” PMID 19380449 ↗ Apr 2009 “To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma” NCT00830895 ↗ “they receive the EveroHT regimen (everolimus plus trastuzumab and docetaxel) for two cycles.” NCT07239271 ↗ “4. Exemestane 25mg + everolimus 10mg oral administration every day (1 cycle = 4 weeks)” NCT06837792 ↗ “DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days” NCT02900716 ↗ “Treatment with Evero drug-coated balloon to apply local treatment with everolimus” NCT07144150 ↗ “• A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus)” NCT07124078 ↗ “• A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus)” NCT06821542 ↗ “everolimus has been shown to have single agent activity in relapsed myeloma” NCT01889420 ↗ “The study allowed SOC regimen is tacrolimus + sirolimus or everolimus.” NCT06552169 ↗ “Everolimus (10 mg orally once daily on day 1 to 28 in a 28 day cycle)” NCT06849947 ↗ “Everolimus will be continued if already started before the inclusion” NCT06254248 ↗ “mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “MTOR inhibitor + anti-estrogen therapy (everolimus + exemestane)” NCT04965688 ↗ “All patients were to receive 10mg everolimus (RAD001) daily.” NCT00529802 ↗ “RAD001 (everolimus) is a novel oral derivative of rapamycin.” NCT01047293 ↗ “Patients receive oral everolimus on days 1, 8, 15, and 21.” NCT00680758 ↗ “A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)” NCT01096199 ↗ “CB-839 in combination with standard dose everolimus” NCT02071862 ↗ “DTRM-555 (DTRMWXHS-12, everolimus and pomalidomide)” NCT04305444 ↗ “Drug: Lapatinib Drug: Everolimus Drug: Sorafenib” NCT03768375 ↗ “for AMG479 (ganitumab) and RAD001 (everolimus).” NCT01122199 ↗ “This group will receive Tacrolimus+Everolimus.” NCT01707849 ↗ “Everolimus, 5 mg/day orally continuously.” NCT07522801 ↗ “RAD001 (everolimus) 10 mg per os daily.” NCT01625520 ↗ “Everolimus: 10mg PO daily 16-18 weeks” NCT01163929 ↗ “Etoposide Everolimus Fludarabine” NCT02551718 ↗ “RAD001 (everolimus) + Cisplatin” NCT00858663 ↗ “1. PIK3CA, PTEN: Everolimus” NCT02101385 ↗ “mTOR inhibitors: Everolimus” NCT07173556 ↗ “exemestane plus everolimus” NCT04869943 ↗ “Everolimus (delayed)” NCT04104438 ↗ “RAD001 (everolimus)” NCT00303732 ↗ “RAD001 (Everolimus)” NCT01198665 ↗ “RAD001 (Everolimus)” NCT00449748 ↗ “RAD001 (everolimus)” NCT01042782 ↗ “RAd001 (Everolimus)” NCT01731158 ↗ “Everolimus” NCT02142036 ↗ |
| Known as | Afinitor | “Everolimus (Afinitor) is a single agent which was evaluated and demonstrated efficacy in randomized phase III study (RECORD-1) in metastatic RCC patients after failure of...” NCT02056587 ↗12“An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function” NCT00968591 ↗ “Therefore, everolimus (Afinitor®) is being tested in specific diseases to stop cells from growing too fast (as in cancer).” NCT02188550 ↗ “test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults” NCT06658093 ↗ “Everolimus (Afinitor) 10 mg tablet once daily.” NCT01865747 ↗ “Oral Everolimus (RAD001, Afinitor®)” NCT01379521 ↗ “Everolimus (Afinitor) tablets” NCT07435584 ↗ “Everolimus (Afinitor®)” NCT02113800 ↗ “Everolimus (Afinitor®)” NCT06680921 ↗ “Everolimus (Afinitor®)” NCT06789900 ↗ “Everolimus (Afinitor®)” NCT01801137 ↗ “Afinitor (everolimus)” NCT03198949 ↗ |
| Known as | AfinitorTM | “Everolimus (AfinitorTM) is approved by the FDA for the treatment of advanced renal cell carcinoma” NCT01061788 ↗ |
| Known as | Afintor | “* Everolimus (Afintor™) is a pill that works by blocking the activity of a substance in the body known as mTOR (mammalian target of rapamycin).” NCT01055795 ↗ |
| Known as | BU-Everolimus | “Drug: BU-Everolimus” NCT01023542 ↗ |
| Known as | Certican | “Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation” NCT01706471 ↗13“everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml” NCT01028092 ↗ “Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression” NCT00828503 ↗ “Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.” NCT01023815 ↗ “Commercially available everolimus (Certican®), oral route, was used.” NCT02864706 ↗ “Everolimus (Certican®) and reduced dose of Cyclosporine A (Neoral®)” NCT02328963 ↗ “Patients will received everolimus (CERTICAN), oral form” NCT03955172 ↗ “Everolimus (Certican)” NCT00098007 ↗ |
| Known as | Certirobell | “This study aims to evaluate the efficacy and safety of everolimus (Certirobell®) as adjuvant therapy in high-risk HCC patients following curative resection.” NCT06972758 ↗ |
| Known as | ERL | “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗ |
| Known as | EVE | “We subsequently tested the effects of transient versus chronic inhibition of autophagy with chloroquine or hydroxychloroquine (HCQ) and mTOR signaling with rapamycin (RAPA) or...” PMID 40897974 ↗ Sep 20254“We report a single-center phase I/II trial exploring the combination of everolimus (EVE) and mycophenolate mofetil (MMF) as calcineurin inhibitor (CNI)-free GVHD prophylaxis” PMID 33755792 ↗ Mar 2021 “Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models.” PMID 36840749 ↗ Feb 2023 “Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients” NCT01927588 ↗ “patients receiving everolimus (EVE) and exemestane (EXE)” PMID 33413212 ↗ Jan 2021 |
| Known as | Everolimus: Certican | “Everolimus: Certican®” NCT01509560 ↗ |
| Known as | EVL | “Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS)...” NCT04936971 ↗2“followed by either steroid withdrawal (CsA/MPA) or replacement of cyclosporine with everolimus (EVL)” PMID 33277746 ↗ Dec 2020 “Drug: Everolimus(EVL)” NCT02137239 ↗ |
| Known as | EVR | “Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to...” PMID 39490986 ↗ Oct 202410“Participants were randomised (1:1) to receive everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) or mycophenolic acid with standard-exposure CNI (MPA+sCNI).” PMID 34620664 ↗ Oct 2021 “Everolimus (EVR) was associated with lower incidence of viral infections and also the lowest incidence of neoplasms.” NCT01653041 ↗ “were randomized to receive everolimus (EVR) + mycophenolic acid (MPA) or were maintained on tacrolimus (TAC) + MPA.” PMID 27648523 ↗ Oct 2016 “Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV.” PMID 30312541 ↗ Nov 2018 “and everolimus (EVR), have distinct pharmacokinetic/pharmacodynamics properties.” PMID 37525373 ↗ Aug 2023 “receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52)” PMID 32406111 ↗ Jun 2020 “start everolimus+reduced tacrolimus (EVR+rTAC)” PMID 29237235 ↗ Jan 2018 “everolimus (EVR), low-dose tacrolimus (LTac)” PMID 28141897 ↗ Mar 2017 “everolimus (EVR) + reduced tacrolimus (TAC)” PMID 28817434 ↗ Dec 2017 “everolimus (EVR)” PMID 33988338 ↗ Feb 2022 |
| Known as | RAD | “This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression.” NCT00149981 ↗ |
| Known as | RAD-001 | “This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and...” NCT00414440 ↗180“We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional chemotherapy, in AML patients under 65 years of age at first...” PMID 23321953 ↗ Jan 2013 “A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing...” PMID 22160854 ↗ Dec 2011 “North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed...” PMID 20864273 ↗ Sep 2010 “Everolimus (RAD-001) is an orally active rapamycin analogue shown in preclinical data to produce cytostatic cell inhibition, which may be potentially beneficial in treating melanoma.” PMID 29666297 ↗ Apr 2018 “A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)” NCT00936702 ↗ “UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib alone” NCT03139747 ↗ “A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer.(RHOMUS)” NCT00943956 ↗ “RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.” PMID 23725999 ↗ May 2013 “RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone.” NCT00496600 ↗ “Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.” PMID 23357973 ↗ Aug 2014 “Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients” NCT00170833 ↗ “This is an open-label, multicenter, single-arm, phase II clinical trial of Everolimus (RAD001) in patients with segmental overgrowth syndrome.” NCT02569125 ↗ “A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer” NCT01061788 ↗ “A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors” NCT00423865 ↗ “Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity” NCT01024946 ↗ “Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)” NCT00968253 ↗ “A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)” NCT01334502 ↗ “Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors” NCT01482156 ↗ “SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).” PMID 25611229 ↗ Feb 2015 “Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR)” PMID 16951235 ↗ Sep 2006 “Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine” NCT00560963 ↗ “Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting.” NCT01626222 ↗ “Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.” PMID 24013904 ↗ Sep 2013 “whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001).” PMID 19380449 ↗ Apr 2009 “Everolimus (RAD001), a rapamycin analogue, is an orally administered inhibitor of mTOR.” NCT01283789 ↗ “Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer” NCT00519324 ↗ “RAD001 is an orally administered cell cycle inhibitor with antitumor activity.” NCT00827567 ↗ “Everolimus (RAD001), a new inhibitor for mammalian target of rapamycin (mTOR)” PMID 24886512 ↗ May 2014 “RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg.” NCT01148628 ↗ “Everolimus (RAD001) is a novel oral derivative of rapamycin.” NCT00805129 ↗ “RAD001 (Everolimus), an inhibitor of the mTOR molecule” NCT00567554 ↗ “Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily” NCT01412515 ↗ “RAD001 (Everolimus) in combination with carboplatin” NCT00930475 ↗ “experimental drug RAD001C (RAD001, Everolimus)” NCT00187174 ↗ “Everolimus (RAD001) 4 mg initial daily dose.” NCT00170846 ↗ “Everolimus (RAD001) with MMF and Steroids” NCT03596970 ↗ “Oral Everolimus (RAD001, Afinitor®)” NCT01379521 ↗ “Everolimus (RAD-001) and Gefitinib” NCT00085566 ↗ “Everolimus is also called RAD001.” NCT01252251 ↗ “Letrozole and RAD001 (Everolimus)” NCT01068249 ↗ “Gefitinib and Everolimus (RAD001)” NCT00096486 ↗ “BEZ235 plus everolimus (RAD001)” NCT03373903 ↗ “Everolimus (RAD001) , Afinitor®” NCT01419639 ↗ “Everolimus (also called RAD001)” NCT01182168 ↗ “Drug: Everolimus (RAD001)” NCT00369161 ↗ “Drug: RAD001(everolimus)” NCT00719264 ↗ “Everolimus (RAD 001)” NCT01111058 ↗ “Everolimus (RAD001)” NCT01857193 ↗ “everolimus (RAD001)” NCT00426530 ↗ “RAD001 (Everolimus)” NCT01954693 ↗ “Everolimus (RAD001)” NCT00788060 ↗ “Everolimus (RAD001)” NCT00154297 ↗ “RAD001 (everolimus)” NCT01167530 ↗ “Everolimus (RAD001)” NCT00419159 ↗ “everolimus (RAD001)” NCT00792766 ↗ “Everolimus (RAD001)” NCT00531063 ↗ “Everolimus (RAD001)” NCT01365468 ↗ “Everolimus (RAD001)” NCT01548807 ↗ “Everolimus (RAD001)” NCT00531440 ↗ “Everolimus (RAD001)” NCT01595009 ↗ “Everolimus (RAD001)” NCT00857259 ↗ “Everolimus (RAD001)” NCT00371826 ↗ “Everolimus (RAD001)” NCT00170794 ↗ “RAD001: Everolimus” NCT01412892 ↗ “RAD001(Everolimus)” NCT00636922 ↗ “RAD001” NCT01009801 ↗ |
| Known as | RAD001 (Everolimus) | “RAD001 (Everolimus)” NCT01226056 ↗3“RAD001 (Everolimus)” NCT01063478 ↗ “RAD001 (everolimus)” NCT01042782 ↗ “RAD001-Everolimus” NCT00613132 ↗ |
| Known as | RAD001C | “experimental drug RAD001C (RAD001, Everolimus)” NCT00187174 ↗ |
| Known as | sirolimus | “Everolimus (sirolimus) is an inhibitor of the mammalian target of rapamycin (mTOR).” NCT07095933 ↗ |
| Known as | Votubia | “Verum and placebo were provided by Novartis (Basel, Switzerland), including funding to cover the manufacturing and provision of everolimus (Votubia) tablets and the...” PMID 36049557 ↗ Aug 2022 |
| Known as | Zortress | “The purpose of this study is to test the safety and effectiveness of everolimus (Zortress®) in preventing antibody formation in patients with chronic failing kidney transplants.” NCT01636466 ↗4“Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation” NCT02736227 ↗ “Patients are supplied everolimus (Zortress) + prograf” NCT01911546 ↗ “Zortress® /Everolimus” NCT01612299 ↗ “Zortress” NCT07634601 ↗ |
| Action | Inhibit | “designed to block proteins that are important in the development and growth of cancer” NCT00081874 ↗ |
| Modality | Small molecule | “Everolimus is a semisynthetic macrocyclic lactone” NCT00117702 ↗ |
| Route | Oral | “you will receive treatment with RAD001 by mouth every day” NCT00081874 ↗ |
| Target | MTOR | “the mammalian target-of-rapamycin inhibitor everolimus” PMID 20871262 ↗ Oct 2010 |